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Background: Burn injury is exacerbated by inhalation injury, causing higher morbidity and 
mortality rates compared to those with a comparable burn injury alone. The complex patho-
physiology of inhalation injury is well described, but analysis of treatment is a mammoth task 
and requires individual focus on a number of components of management. In this case, the 
focus of the review is treatment of inhalation injury using pharmacological means. It provides 
a concise overview of the disease process and a summary of the evidence for speciﬁ  c manipula-
tion of various disease pathways.
Methods: A literature search through PubMed was completed and all links and bibliography 
reference articles were explored.
Results: A total of 47 papers matched the search terms. Of these, one was a comparative study 
with historical controls, 2 were retrospective case series, 2 studies reported a single human case 
series, 34 were examinations in animals, and 8 were expert opinion or reviews.
Conclusion: The literature illustrates the complicated immuno-biochemical pathways that have 
conﬂ  icting roles and importance, complicating integrated understanding. Secondly, there is an 
almost complete absence of high quality data from humans. Clinical use of pharmaco-therapies 
for inhalation injuries is further limited by the lack of commercial availability.
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Introduction
In the United States, of the estimated 2 million burns per year, 100,000 require hospi-
talization, and 5000 result in death (Herndon and Spies 2001). Burns are exacerbated 
by inhalation injury, and associated pulmonary complications (Murakami and Traber 
2003). Prevalence rates vary but authors concur that those with combined burn and 
inhalation injury have higher morbidity and mortality rates than those with comparable 
burn injury alone (Tasaki et al 2002; Cox et al 2003; Endorf and Gamelli 2007). Data 
from the Royal Perth Hospital (RPH) Western Australia, conﬁ  rms that inhalation 
injury causes more deaths and increased bed days and resource usage than burns 
alone (Table 1). Further, it is proposed that acute lung injury (ALI) and resultant acute 
respiratory distress syndrome (ARDS) account for up to 75% of the deaths related to 
ﬁ  re (PatientPlus 2007).
The patho-physiology of inhalation injury is well described in the literature, 
though the vast majority of studies have been completed in the animal model (Table 2) 
(Enkhbaatar and Traber 2004; Lee and Mellins 2006; Cancio et al 2007). In brief, 
inhalation injury is the result of thermal or chemical injury to the airways and alveoli 
from exposure to superheated gases, steam, hot liquids and, or toxic products of 
incomplete combustion (Herndon et al 1986). Dry heat does not easily penetrate to 
the lower respiratory tract, and hence true thermal damage of the lung parenchyma is 
rare (Cox et al 2003). Tissue damage above the vocal cords is often the result of direct 
thermal exposure while below the cords, injury is generally caused by chemical toxins Drug Design, Development and Therapy 2008:2 10
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and particulate matter (Mlcak et al 2007). The by products 
of combustion; namely hydrogen cyanide, aldehydes, hydro-
chloric acid, acrolein, ammonia, chlorine, sulphur dioxide, 
and nitrogen dioxide, that are chieﬂ  y responsible for initial 
pulmonary tissue insult (Haponik et al 1988).
Armed with the data and the knowledge of acute lung 
injury patho-physiology (Figure 1), the multi-disciplinary 
burns team (MBT) wished to examine ways of improving 
outcomes in the inhalation injury group. The ﬁ  rst step towards 
implementing evidenced-based practice is to review the 
relevant literature (Eccles and Grimshaw 2004).
Aims
Due to the complexity of the body’s response to inhala-
tion injury, the RPH MBT decided to focus initially on 
pharmacological management. The aims of this review are 
therefore to:
•  Determine the pharmacological options for management 
of inhalation injury; and
•  Examine the levels of evidence to support various 
pharmacological interventions.
Methods
An on-line literature search through PubMed was completed 
using the following search terms: “inhalation injury”, 
“burn*”, “pharmacomanagement”, and “medication*”. Where 
possible, all links and bibliography reference articles were 
explored.
Results
A total of 47 papers including 1 internet citation matched 
the search terms. Of the papers, one was a human case 
series with historical controls (n = 90), 2 were retrospective 
descriptive case series (n = 80, n = 98), 2 studies reported 
an overlapping human case series (n = 6), 34 were exami-
nations in animals, 8 were expert opinion or reviews and 
the remainder were from non-reliable or public relations 
sources.
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Figure 1 Flow diagram describing the patho-physiological pathways involved in the body’s response to inhalation injury (and burns).Drug Design, Development and Therapy 2008:2 11
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Table 3 presents the results of the review according to the 
etiology of the negative effects of inhalation injury.
Discussion
PubMed is a well recognized ﬁ  rst contact database for high 
proﬁ  le journals and high impact medical literature. War-
ranted, this paper does not provide an exhaustive literature 
search. but the likelihood is that the results represent the 
current medical practice in pharmaco-management of inha-
lation injury.
The primary aim of this study was to determine the level 
of evidence in order to determine best practice. In summary, 
according to the Australian National Health and Medical 
Research Council (NH&MRC) guidelines (1999), at best 
this review suggests, level III-3 evidence (comparative 
study, historical controls) for the clinical use of alternating 
nebulized heparin alternating with the mucolytic agent, 
acetylcystine. Secondly, the review reveals level IV (case 
series) evidence promotes short term positive effects from 
aerosolized surfactant and negative outcomes associated with 
prophylactic antibiotics and corticosteroid use to ameliorate 
acute inhalation injury.
The ﬁ  rst aim of this review was to examine the options 
for manipulation of the inﬂ  ammatory pathways using 
medication. The ﬁ  ndings are discussed in detail below 
with reference to the patho-physiological pathways in 
Table 2.
Nitric oxide (NO)
Increased inducible nitric oxide synthase (iNOS) and resul-
tant NO levels have been isolated in lung tissue as a result 
of inhalation injury (Enkhbaatar et al 2003). Up-regulation 
of cytokines, primarily interleukin-1, and endotoxin release 
are implicated as causes for NO presence as both are found 
in increased amounts after burn and inhalation injury. 
Increased levels of NO lead to loss of hypoxic vasocon-
striction. Murakami and Traber (2003) reported the ensuing 
vasodilation leads to an increase in bronchial blood ﬂ  ow by 
up to 800%. Additionally, loss of hypoxic vasoconstriction 
allows poorly ventilated lung segments to receive increased 
blood ﬂ  ow (Enkhbaatar and Traber 2004). This creates ven-
tilation/perfusion mismatch, increases the pulmonary shunt 
fraction, and overall results in lower oxygen saturations in 
the blood.
Furthermore, Enkhbaatar and Traber (2004) comment 
that increased respiratory compromise is created by the 
oxidizing and nitrating action of high concentrations of NO. 
Nitrous oxide becomes cytotoxic and a pro-inﬂ  ammatory 
agent by reacting with O2
− to form peroxynitrate (ONOO−). 
Peroxynitrate causes oxidation and nitration, producing 
further tissue damage and lung inﬂ  ammation (Enkhbaatar 
and Traber 2004).
To reduce nitric oxide production, Enkhbaatar and 
colleagues (2003) examined the use of an iNOS inhibitor, 
BBS-2, on sheep. BBS-2 showed beneﬁ  cial effects on pul-
monary gas exchange and shunt fraction, lung lymph ﬂ  ow, 
lung water content, airways obstruction, airways blood ﬂ  ow 
and airways pressures.
Cyclooxyganase (COX) pathway
Elevated prostacyclin and thromboxane A2 are signiﬁ  cantly 
elevated post burn and smoke inhalation (Kimura, Traber 
et al 1988). Both are produced by the action of the enzyme 
Table 1 Burn patient data from RPH, comparing inhalation injury statistics with burns of comparable TBSA and all burns admitted 
between 2004–Oct 2006
Mean burn patient data  Inhalation injury  Signiﬁ  cant burns  All burns admitted
 (n  = 32)  (n = 79) (20%TBSA*) (n  = 717)
Age (yrs) (SD)  41.9 (19.8)  41.3 (16.8)  38.9 (17.7)
TBSA (%) (SD)  20.6 (24.1)  34.5 (17.5)  8.4 (11.2)
ICU LOS (dys) (SD)  4.7 (9.9)  3.1 (8.5)  0.43 (3.0)
Total LOS (dys) (SD)  27.5 (36.0)  27.1 (29.5)  10.9 (15.5)
Operations# (SD)  1.4 (2.2)  1.8 (1.8)  0.6 (1.0)
Mortality Rate (%)  6.3  3.8  1.0
*TBSA – Total burn surface area.
#Number of surgical skin reconstruction procedures.
(SD) – Standard deviation of measure.
Table 2 Pathophysiological processes that have been linked to 
the etiology acute lung injury post smoke inhalation
Airways oxidative stress  Beta 2 – agonists
Airways cast formation  Nitric oxide
Loss of pulmonary surfactants  Eicosanoids – Prostaglandins
Airways bronchoconstriction    – Thromboxane
Neutrophil activation/chemotaxis    – LeukotrienesDrug Design, Development and Therapy 2008:2 12
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COX. A number of studies consequently look at nonsteroidal 
anti-inﬂ  ammatory (NSAID) medications.
Ibuprofen was shown by Stewart and colleagues (1990) 
to reduce early-onset lung water after smoke inhalation 
injury alone, or in combination with a thermal injury in adult 
rabbits. Sakurai and colleagues (1998) demonstrated that 
ibuprofen improved intestinal organ blood ﬂ  ow during the 
acute hypovolemic period. Finally, Kimura and colleagues 
(1988) found that ibuprofen attenuated the elevation of lung 
lymph ﬂ  ow, microvascular permeability and pulmonary 
edema in an ovine model.
The advantage of the nonselective COX inhibitor, ketoro-
lac, is its availability as a parenteral preparation. Enkhbaatar 
and colleagues (2003) showed in sheep that it slowed the 
decline in the PaO2/FiO2 ratio, the increase in lung lymph 
ﬂ  ow and signiﬁ  cantly lowered bronchial obstruction and 
airway pressures. They found that ketorolac had multiple 
favorable pharmacodynamic attributes including signiﬁ  cantly 
less cardiac myocardial contractility depression, hemo-
concentration, and bleeding tendencies.
Conversely, Abdi and colleagues (1995) iterated concern 
regarding the use of ibuprofen. They found that myocardial 
depression seen post inhalation injury is worse in animals 
treated with ibuprofen. This was not seen with ketorolac by 
Enkhbaatar and colleagues (2003).
Other than a strong association, the role of eicosanoids 
in inhalation injury is less well understood. Prostacyclins 
prevent increase in microvascular permeability. Kimura and 
colleagues (1988) propose that the COX inhibition stabilizes 
lysosomal membranes, inhibits leukocyte migration and 
prevents the release of oxygen free radicals. Additionally, 
COX inhibitors are reported to lower plasma NO levels by 
down regulating iNOS (Enkhbaatar et al 2003).
Lipoxygenase pathway
Several studies have implicated leukotrienes in the etiology 
of edema after smoke exposure. Witten and colleagues (1990) 
demonstrated and increase in leukotriene B4 in bronchoal-
veolar lavage (BAL) after inhalation injury in rabbits. They 
further demonstrated that piriprost, a leukotriene synthesis 
inhibitor, given 1 hour prior to smoke exposure resulted in 
attenuation of the swelling in type 1 alveolar cell epithelium, 
BAL leukotriene B4, prostaglandin E2 and thromboxane B2 
levels at 1 hour post smoke exposure. Hales and Musto (1995) 
compared a combined COX and lipoxygenase inhibitor (BW-
755C) to the NSAID, indomethacin. They found that BW-
755C prevented edema, whereas indomethacin did not.
Finally, Janssens and colleagues (1994) compared three 
eicosanoids by inhibiting them in isolation. They gave sheep 
either BW-755C, U-63557A (a speciﬁ  c thromboxane syn-
thetase inhibitor), or indomethacin. They found that neither 
indomethacin nor U-63557A prevented the increase in lymph 
ﬂ  ow or reduced the lung wet-to-dry weight ratio. However, 
these did blunt and delay the rise in airway pressure and the 
rises in pulmonary arterial pressure and pulmonary vascular 
resistance. They concluded that leukotriene B4 may be the 
main oedematogenic eicosanoid. This was echoed by Abdi 
and colleagues (1995) who looked at the effects of ibuprofen 
on bronchial blood ﬂ  ow in the ovine model. They concluded 
that vasodilatory prostaglandins do not play a major role in 
the bronchial vascular response to smoke inhalation injury. 
This last comment conﬂ  icts with the above mentioned COX 
annotations.
B2 agonists/bronchodilators
These are successful in the management of airways pathology 
for conditions such as asthma, causing bronchodilation and 
subsequent increase in airway caliber (Palmieri et al 2006). 
A controlled experiment by Palmieri and colelagues (2006) 
looked at continually nebulized albuterol in sheep. Results 
were promising; with comparison to the control group, those 
given the albuterol had lower pause and peak inspiratory 
pressures, decreased pulmonary trans-vascular ﬂ  uid ﬂ  ux, 
a signiﬁ  cantly higher PaO2/FiO2 ratio and decreased shunt 
fraction.
Oxidative stress
There is increased oxygen-free radical activity after smoke 
inhalation (Maybauer et al 2005). This arises from both direct 
Table 3 Stratiﬁ  ed list of researched pharmaco-intervention 
to the etiology of inhalation injury
Promising experimental results
Anti-oxidants  Beta 2 – agonists
Leukotriene inhibitors  Aerosolised tissue 
 plasminogen  activator
Nebulised heparin ± Acetylcystine  Recombinant anti-thrombin
Nitric oxide inhibition  Nebulised dimethylsulfoxide
Deferoxamine-pentastarch aerosol  Antioxidant lazaroids
Vitamin E  NSAIDs; ketorolac
Mixed experimental results
Parenteral heparin  Inhaled detergent/surfactant
Anti-adhesion (selectin) molecules  NSAIDs (indomethacin,
 ibuprofen)
Experimental results showing no beneﬁ  t or adverse outcomes
Corticosteroids Allopurinol
Manganese superoxide dismutaseDrug Design, Development and Therapy 2008:2 13
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inhalation of oxidizing agents, as well as from a by-product 
of cellular activity. Both the peroxide and hydroxyl ions 
have been implicated, and as noted, peroxynitrate has been 
identiﬁ  ed in oxidization. Oxidization results in damage to 
the pulmonary capillary endothelium, evoking inﬂ  ammation, 
increased microvascular permeability, and edema formation 
(Stothert et al 1990).
Endogenous production of oxidizing agents is mostly 
released from marginating polymorphonuclear leukocytes 
(Brown et al 1988). In an ovine experiment, Murakami 
and Traber (2003) used nitrogen mustard to suppress bone 
marrow. They found, in the leukocyte-depleted sheep, that 
smoke-inhalation pulmonary edema and vascular perme-
ability were prevented. There was also signiﬁ  cantly less 
lipid peroxidation and cellular oxidation (Murakami and 
Traber 2003).
There are a number of methods proposed to curb damage 
associated with oxygen-free radicals. A number of papers 
look at the use of anti-oxidant agents. Brown et al looked at 
the use of dimethylsulfoxide, an O2-free radical scavenger 
(Brown et al 1988). Their trial had four arms; control sham 
group, sheep treated by dimethylsulfoxide or heparin, and 
sheep given both. They found that dimethylsulfoxide sig-
niﬁ  cantly diminished the pulmonary lymphatic response, 
concluding this was a result of attenuated rise in microvas-
cular permeability.
Several other studies showed promising results with 
the administration of various anti-oxidant agents. La 
Londe and colleagues (1994) found that aerosol delivery of 
deferoxamine-pentastarch complex prevented progression to 
pulmonary edema. Three studies by Wang and colleagues 
(1996, 1997, 1999) found that lazaroid analogue U75412E, 
a free radical scavenger, ameliorated interstitial edema. Vita-
min E (alpha-tocopheral) is another example of an oxygen 
superoxide scavenger. Depleted vitamin E levels have found 
to occur after combined burn and inhalation injury (Morita, 
Shimoda et al 2006). Morita and colleagues administered 
aerosolized vitamin E and demonstrated decreased pulmo-
nary oedema and signiﬁ  cant improvement in pulmonary gas 
exchange in sheep with burn and smoke inhalation (Morita, 
Shimoda et al 2006; Morita, Traber et al 2006). In contrast, 
the use of manganese superoxide dismutase, an enzyme that 
converts the superoxide radical to peroxide, was looked at by 
Maybauer and colleagues (2005). They found that nebulized 
delivery to smoke exposed sheep failed to improve lung 
edema or pulmonary gas exchange. Another unsuccessful 
agent is allopurinol. This is proposed to decrease O2
– by its 
inhibition of xanthine oxidase. A study on sheep by Ahn 
and colleagues (1990) looked at the effects of allopurinol on 
sheep. They found no signiﬁ  cant difference in those managed 
with or without allopurinol.
There are several papers looking at approaches to attenu-
ate neutrophil response. The selectin family of anti-adhesion 
molecules mediate neutrophil migration by allowing endothe-
lial cell contact (Katahira et al 2002). In sheep, Katahira and 
colleagues (2002) found that pre-treatment with the antibody 
for L-selectin called leukocyte adhesion molecule (LAM) 1 
hour after smoke exposure decreased the lung lymph ﬂ  ow and 
pulmonary permeability. Similarly, several authors reported 
that the oligosaccharide Sulfo lewis C, a putative ligand of 
E-selectins, attenuated lung injury after smoke exposure 
on sheep (Tasaki et al 1998; Mandel and Hales 2007). In a 
comparable experiment, Chandra and colleagues (2003) gave 
an anti-P-selectin antibody. This did not protect against lung 
injury in sheep exposed to smoke (Chandra et al 2003).
Inﬂ  ammation and airways cast formation
Pathological lung specimens, after inhalation of smoke, 
demonstrate the presence of obstructive casts in the airways. 
In sheep, Cox and Burke (2003) found that casts formed at 
all three studied airways levels (bronchial, bronchiolar and 
terminal bronchiolar). Obstructive changes were maximal at 
24 hours in large airways, and rose continually to the cut of 
time of 72 hours at the bronchiolar level. Casts are composed 
of epithelial cells, neutrophils, mucus and ﬁ  brin. Mucosal 
hyperemia, increased microvascular permeability, acute 
inﬂ  ammatory cell inﬂ  ux, exfoliation of epithelial lining, and 
mucous secretion are the causative factors (Cox et al 2003). 
Airway obstruction leads to further ventilation/perfusion mis-
match, and complications such as atelectasis and pneumonia. 
Barotrauma may ensue from overstretching of alveoli sup-
plied by the remaining patent airways (PatientPlus 2007).
One method to reduce cast formation is the attenuation of 
the inﬂ  ammatory response. The use of anti-inﬂ  ammatories 
and anti-adhesion molecules may be indicated for this rea-
son. In their experiment with dimethylsulfoxide, Brown and 
colleagues (1988) found the administration of this O2-free 
radical scavenger also reduced airways cast formation (pre-
sumably as a succeeding effect).
An alternate approach to over-coming airways obstruc-
tion is the use of heparin. The main action of heparin is 
potentiating anti-thrombin III mediated inactivation of 
thrombin. Heparin may also act as a free radical scavenger 
(Tasaki et al 2002). There have been multiple experiments 
looking at both parenteral and nebulized heparin. Cox 
and colleagues (1993) found that in sheep given a heparin Drug Design, Development and Therapy 2008:2 14
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infusion, there was signiﬁ  cant improvement in oxygenation, 
with less barotrauma and pulmonary edema. At necropsy, 
those treated with heparin had signiﬁ  cantly fewer tracheo-
bronchial casts.
Murakami and colleagues (2002) found that high dose 
heparin attenuated lung dysfunction after combined smoke 
and septic lung injury. They found in histological specimens, 
decreased lung cellular inﬁ  ltrates, lung edema, congesting, 
and cast formation. Their study differed from Cox and 
colleagues (1993), in that the sheep were also exposed to 
Pseudomonas aeruginosa and heparin was administered by 
nebulization. Conversely, Murakami and colleagues (2002, 
2003) in an analogous experiment to one previously reported 
from the same setting, found that high dose heparin did not 
prevent lung dysfunction after combined smoke and septic 
lung injury. In this experiment the heparin was given via 
intravenous infusion. Nebulized heparin was effective in the 
applicable arm in the controlled experiment by Brown and 
colleagues (1988).
More importantly, in a comparative case series with his-
torical controls by Desai and colleagues (1998), the effect 
of giving a regime of aerosolized heparin alternating with a 
solution of 20% acetylcystine was performed on a pediatric 
human population. Acetylcystine is a mucolytic agent, and 
hence should diminish airway cast formation. The study 
included 90 patients with a mean age of 8 years, suffering 
from inhalation injury, diagnosed by bronchoscopy. They 
found a signiﬁ  cantly decreased mortality, incidence of atel-
ectasis, and re-intubation rate in the treatment group.
Another approach to overcoming airways cast obstruction 
is the administration of antithrombin. It should have compa-
rable effects to heparin. This was conﬁ  rmed by Murakami 
and colleagues (2002) in sheep exposed to smoke and septic 
injury an infusion of human recombinant antithrombin.
Lastly, as casts are also composed of ﬁ  brin, Enkhbaatar 
and colleagues (2004) experimented with aerosolised tissue 
plasminogen activator (TPA) in sheep. TPA lyses ﬁ  brin 
clots. They found that TPA, attenuated airways obstruction 
as expected.
Aerosolized surfactant
Within the lung alveoli, there is a delicate balance between 
negative intrathoracic pressure, alveolar wall surface ten-
sion and tissue elasticity. The presence of surfactant lining 
the alveolar walls results in lower alveolar surface tension 
and stabilizes the ﬂ  uid balance in the lung. The removal of 
which allows increased microvascular permeability and sub-
sequent lung edema formation. This has been demonstrated 
in multiple animal experiments (Brendenberg et al 1983; 
Nieman and Brendenberg 1985; Nieman et al 1990; Wang 
et al 1993). Pulmonary surfactant also assists with removal of 
inorganic dust particles, opsonization of bacteria and activa-
tion of alveolar macrophages (Pallua et al 1998).
The loss of surfactant is thought to arise from: direct deac-
tivation or inhibition of the alveolar surfactant by oxidants, 
proteases, ﬁ  brin and protein rich exudate; incorporation of 
hyaline membranes in ﬁ  brin polymers; lifting of the surfac-
tant away from the alveolar wall by edema; and disturbed 
synthesis resultant of damage to the type II pneumatocytes 
(Wang et al 1993).
The beneﬁ  t of surfactant therapy has been demonstrated 
in the context of ARDS and infant respiratory distress 
syndrome (Wang et al 1993). However, there is a dearth 
of literature regarding it application in the setting of burns. 
Pallua and colleagues (1997, 1998) provides two case series 
of 4 and 2 patients respectively, with severe burns and poor 
prognosis that beneﬁ  ted from surfactant therapy. After the 
limits of mechanical ventilation had been reached, they 
introduced intrabronchial surfactant via bronchoscopy. They 
subsequently found that there was temporary improved gas 
exchange, an increase in arterial oxygenation (PaO2), a 
reduction in required inspiratory O2 concentration (FiO2), 
and improved lung compliance (Wang et al 1993; Pallua 
et al 1997).
Steroids
Controlled experiments thus far looking at the useful-
ness of steroids in burn and inhalation injuries have been 
disappointing. No direct data support their use in smoke 
inhalation and this was conﬁ  rmed by a recent disaster 
case series report (Herndon et al 1988; Cha et al 2007). 
In fact, due to their immuno-suppressive effects, steroids 
are likely to lead to the increased risk of infection and 
delayed wound healing. Nieman and colleagues (1991) 
found in sheep, that methylprednisolone did not protect 
the lung from the acute physiological consequences of 
inhalation injury.
Prophylactic antibiotics
Pulmonary infection is a sequela of inhalation injury, and 
hence antibiotic prophylaxis is not considered here in depth. 
Patients with pulmonary damage from inhalation injury are 
at increased risk for secondary bacterial infection, com-
monly Staphylococcus aureus and P. aeruginosa. Though 
appealing in concept, usage of antibiotics is recommended 
on clinical grounds of deﬁ  nitive microbiologic evidence Drug Design, Development and Therapy 2008:2 15
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of infection only (Herndon et al 1987). Administration of 
prophylactic antibiotics increases the risk of resistant organ-
ism emergence.
Clinical implications and future 
studies
The research on inhalation injuries thus far has given 
important insight into the etiology and potential pharmaco-
interventions. The amalgamated algorithm outlining the key 
patho-physiological steps also highlights the various points 
at which interventions have been proposed (Figure 1).
Of note, there are several parallel pathways that eventually 
result in organ hypoxemia, suggesting that multiple medica-
tions may be warranted in for meaningful intervention. This 
was illustrated in the study by Brown and colleagues (1988) 
who looked at the use of heparin and dimethylsulfoxide. 
Both of the groups treated with either of these performed 
favorably but those given both outperformed those given 
either preparation alone.
The physical management of pulmonary edema, airway 
obstruction by cast formation and sputum, ventilation/perfu-
sion mismatch and atelectasis was not within the scope of this 
review. Ventilation strategies as well as physical (or respira-
tory) therapy are obvious adjuncts to pharmaco-therapy and 
must be considered as part of a multi-disciplinary approach 
to improving inhalation injury outcomes. The recent review 
paper by Cancio and colleagues (2007) provides an excel-
lent summary of ventilation and artiﬁ  cial lung strategies for 
management of inhalation injury. Finally, cell replacement 
therapies delivered into the lungs remain a largely unexplored 
but promising area with respect to ‘surgical’ management of 
tissue damage in the lungs after inhalation injury (Duncan 
et al 2005).
Conclusion
There are several striking limitations of the literature. 
Firstly, the discussion illustrates the complicated immuno-
biochemical pathways that have conﬂ  icting roles and impor-
tance throughout the journal papers, complicating integrated 
understanding. The experiments and hypotheses generally 
only consider one process in isolation. Secondly, there is a 
complete absence of high quality data collected from humans. 
At best, human case series data supports short term positive 
effect from aerosolized surfactant and, negative outcomes 
from prophylactic antibiotics and corticosteroid use.
It is fair to comment, within the ‘ABC’ paradigm of burns 
care, with satisfactory airways and circulatory management 
strategies, the ability to control the inﬂ  ammatory response of 
the lungs with medication lags in comparison. The advances in 
the management of inhalation injuries may well herald the next 
signiﬁ  cant step forward in severe burn management. However, 
thus far, the clinical use of pharmaco-therapies for inhalation 
injuries is limited by the lack of commercial availability, dearth 
of human trials and confounding experimental results.
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